Akoya Biosciences (AKYA) and Enable Medicine announced a collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community. The Enable Atlas is curated, standardized, and commercially licensable. It provides immediate value to biopharma researchers and AI model developers seeking to accelerate biomarker discovery, drug development, and translational insights. “The Enable Atlas is a catalytic resource for our customers,” said Niro Ramachandran, Chief Business Officer at Akoya Biosciences. “Biopharma customers now have the potential to generate new hypotheses from existing data, increase the statistical power of their studies, and identify novel cellular phenotypes at a scale never before possible.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences, STCC partner on SUPER study for cancer immunophenotyping
- Akoya Biosciences price target lowered to $1.65 from $2.40 at Piper Sandler
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion
- Tikvah intends to vote against Quanterix’s proposed merger with Akoya
- Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens